Cite
HARVARD Citation
Coyle, T. et al. (n.d.). Phase I study of BAY 94‐9027, a PEGylated B‐domain‐deleted recombinant factor VIII with an extended half‐life, in subjects with hemophilia A. Journal of thrombosis and haemostasis. pp. 488-496. [Online].